Literature DB >> 23492765

Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort--a factor analysis.

Laure Dossus1, Annekatrin Lukanova, Sabina Rinaldi, Naomi Allen, Anne E Cust, Susen Becker, Anne Tjonneland, Louise Hansen, Kim Overvad, Nathalie Chabbert-Buffet, Sylvie Mesrine, Francoise Clavel-Chapelon, Birgit Teucher, Jenny Chang-Claude, Heiner Boeing, Dagmar Drogan, Antonia Trichopoulou, Vasiliki Benetou, Christina Bamia, Domenico Palli, Claudia Agnoli, Rocco Galasso, Rosario Tumino, Carlotta Sacerdote, H Bas Bueno-de-Mesquita, Fränzel J B van Duijnhoven, Petra H M Peeters, N Charlotte Onland-Moret, Maria-Luisa Redondo, Noémie Travier, Maria-Jose Sanchez, Jone M Altzibar, Maria-Dolores Chirlaque, Aurelio Barricarte, Eva Lundin, Kay-Tee Khaw, Nicholas Wareham, Veronika Fedirko, Isabelle Romieu, Dora Romaguera, Teresa Norat, Elio Riboli, Rudolf Kaaks.   

Abstract

A "Western" lifestyle characterized by physical inactivity and excess weight is associated with a number of metabolic and hormonal dysregulations, including increased circulating estrogen levels, hyperinsulinemia, hyperglycemia, and chronic inflammation. The same hormonal and metabolic axes might mediate the association between this lifestyle and the development of endometrial cancer. Using data collected within the European Prospective Investigation into Cancer and Nutrition (EPIC), a prospective cohort study carried out in 10 European countries during 1992-2000, we conducted a factor analysis to delineate important components that summarize the variation explained by a set of biomarkers and to examine their association with endometrial cancer risk. Prediagnostic levels of testosterone, androstenedione, dehydroepiandrosterone sulfate, sex hormone-binding globulin, estrone, estradiol, C-peptide, insulin-like growth factor-binding proteins 1 and 2, adiponectin, high- and low-density lipoprotein cholesterol, glucose, triglycerides, tumor necrosis factor (TNF) α, soluble TNF receptors 1 and 2, C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist were measured in 233 incident endometrial cancer cases and 446 matched controls. Factor analysis identified 3 components associated with postmenopausal endometrial cancer risk that could be labeled "insulin resistance/metabolic syndrome," "steroids," and "inflammation" factors. A fourth component, "lipids," was not significantly associated with endometrial cancer. In conclusion, besides the well-known associations of risk with sex hormones and insulin-regulated physiological axes, our data further support the hypothesis that inflammation factors play a role in endometrial carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23492765     DOI: 10.1093/aje/kws309

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  47 in total

1.  Dietary insulin index and insulin load in relation to endometrial cancer risk in the Nurses' Health Study.

Authors:  Jennifer Prescott; Ying Bao; Akila N Viswanathan; Edward L Giovannucci; Susan E Hankinson; Immaculata De Vivo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-23       Impact factor: 4.254

2.  Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium.

Authors:  P M Webb; R Na; E Weiderpass; H O Adami; K E Anderson; K A Bertrand; E Botteri; T M Brasky; L A Brinton; C Chen; J A Doherty; L Lu; S E McCann; K B Moysich; S Olson; S Petruzella; J R Palmer; A E Prizment; C Schairer; V W Setiawan; A B Spurdle; B Trabert; N Wentzensen; L Wilkens; H P Yang; H Yu; H A Risch; S J Jordan
Journal:  Ann Oncol       Date:  2019-02-01       Impact factor: 32.976

3.  Insulin is an important risk factor of endometrial cancer among premenopausal women: a case-control study in China.

Authors:  Yanli Shao; Shijie Cheng; Jianqing Hou; Ying Zuo; Wei Zheng; Min Xia; Nan Mu
Journal:  Tumour Biol       Date:  2015-10-29

Review 4.  Considering the value of dietary assessment data in informing nutrition-related health policy.

Authors:  James R Hébert; Thomas G Hurley; Susan E Steck; Donald R Miller; Fred K Tabung; Karen E Peterson; Lawrence H Kushi; Edward A Frongillo
Journal:  Adv Nutr       Date:  2014-07-14       Impact factor: 8.701

5.  Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease.

Authors:  Ronald C Eldridge; Nicolas Wentzensen; Ruth M Pfeiffer; Louise A Brinton; Patricia Hartge; Chantal Guillemette; Troy J Kemp; Ligia A Pinto; Britton Trabert
Journal:  Cancer Causes Control       Date:  2020-02-25       Impact factor: 2.506

6.  Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop.

Authors:  Danielle M Carrick; Anil K Chaturvedi; Meredith S Shiels; Rao L Divi; Kelly K Filipski; Elizabeth F Hebert; Mukesh Verma; Allan Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-24       Impact factor: 4.254

Review 7.  Hyperinsulinaemia in cancer.

Authors:  Emily J Gallagher; Derek LeRoith
Journal:  Nat Rev Cancer       Date:  2020-09-09       Impact factor: 60.716

8.  Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis.

Authors:  Xiaochen Zhang; Jennifer Rhoades; Bette J Caan; David E Cohn; Ritu Salani; Sabrena Noria; Adrian A Suarez; Electra D Paskett; Ashley S Felix
Journal:  Int J Gynecol Cancer       Date:  2019-08-26       Impact factor: 3.437

9.  Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma.

Authors:  Qiong Gan; Suzanne Crumley; Russell R Broaddus
Journal:  Int J Gynecol Pathol       Date:  2019-01       Impact factor: 2.762

Review 10.  Obesity as an immune-modifying factor in cancer immunotherapy.

Authors:  Robert J Canter; Catherine T Le; Johanna M T Beerthuijzen; William J Murphy
Journal:  J Leukoc Biol       Date:  2018-05-15       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.